Shares of Tango Therapeutics (TNGX) jumped more than 47% after the company reported early results from its Phase 1/2 trial combining Vopimetostat with Revolution Medicines' RAS(ON) inhibitor Daraxonrasib. The study demonstrated a 92% objective response rate in patients with advanced pancreatic ductal adenocarcinoma (PDAC), a cancer type long resistant to treatment.
The trial enrolled patients with MTAP-deleted and RAS-mutant metastatic PDAC who had already received prior therapies. At six months, 90% of participants remained progression-free, with median progression-free survival not yet reached, underscoring the durable benefit. Both Vopimetostat plus Daraxonrasib and Vopimetostat plus Zoldonrasib were generally well tolerated.
CEO Malte Peters highlighted the potential of this chemotherapy-free approach, noting that the synergy between PRMT5 inhibition and RAS blockade may offer a new treatment option for pancreatic cancer patients who face limited options. The company plans to advance the Vopimetostat-Daraxonrasib combination into Phase 3 development for first-line MTAP-deleted pancreatic cancer later this year.
Experts at Dana-Farber Cancer Institute emphasized the importance of these findings, pointing out that chemotherapy has long been the standard of care despite its tolerability challenges and limited efficacy. Precision-guided, targeted therapies could mark a turning point for patients battling this aggressive disease.
Upcoming milestones in second half of 2026 include:
-Initiation of Phase 3 trial for Vopimetostat plus Daraxonrasib in front-line pancreatic cancer.
-Readout of Vopimetostat monotherapy in lung cancer.
-Advancement of TNG456 program in glioblastoma (GBM) with initial data expected.
-Present 2/3L PDAC Vopimetostat + RAS(ON) inhibitors combination data at a scientific conference.
- Initiate Phase 1/2 Vopimetostat + ERAS-0015 combination study.
TNGX has traded between $3.12 and $28.41 over the past year. The stock closed Friday trading (June 5, 2026) at $20.22, down 8.71%. In pre-market trading, the stock is at $29.88, up 47.77%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.